Disease · EFO_0022861
chronic back pain
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. chronic back pain. Diseases, record EFO_0022861. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0022861
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- chronic back pain
- Open Targets ID
- EFO_0022861
- Highest stage of its drugs
- Phase 3, for 3 of its 14 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs14
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BUPRENORPHINE | CHEMBL511142 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CANNABINOL | CHEMBL74415 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| OXYCODONE | CHEMBL656 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CARBIDOPA | CHEMBL1200748 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| KETAMINE | CHEMBL742 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEVODOPA | CHEMBL1009 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NAPROXEN | CHEMBL154 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TESTOSTERONE CYPIONATE | CHEMBL1201101 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CANNABIDIOL | CHEMBL190461 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| DRONABINOL | CHEMBL465 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 14
See all 14 drugsTargets17
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| OPRM1 | Mu-type opioid receptor | 4 | Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 3 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 2 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Phase 1/2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| OPRK1 | Kappa-type opioid receptor | 2 | Kappa opioid receptor agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 3 | https://conductscience.org/library/genes/4986 | Drugs and targets |
| AR | Androgen receptor | 1 | Androgen Receptor agonist | Phase 2 | https://conductscience.org/library/genes/367 | Drugs and targets |
| DDC | Aromatic-L-amino-acid decarboxylase | 1 | DOPA decarboxylase inhibitor | Phase 2 | https://conductscience.org/library/genes/1644 | Drugs and targets |
| DRD3 | D(3) dopamine receptor | 1 | Dopamine D3 receptor agonist | Phase 2 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| GRIN1 | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2902 | Drugs and targets |
| GRIN2A | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2903 | Drugs and targets |
| GRIN2B | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2904 | Drugs and targets |
| GRIN2C | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2905 | Drugs and targets |
1 to 10 of 17
See all 17 targetsTrials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01549652 | 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence | Not applicable | 133 | 2019-01-07 | Opioid Withdrawal, Physical Dependence | MORPHINE, NALOXONE, ONDANSETRON | Its record names the disease | ClinicalTrials.gov |
| NCT04220489 | Perioperative Ketamine in Opioid-Tolerant Patients Undergoing Lumbar Spine Surgery | Phase 2 | 1 | 2024-01-30 | Opioid Dependence, Chronic Pain | KETAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT00315887 | The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain. | Phase 3 | 250 | Chronic Low Back Pain | BUPRENORPHINE | Its record names the disease | ClinicalTrials.gov | |
| NCT05463367 | Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure | Phase 2 | 60 | Opioid Use, Opioid Dependence, Opioid-use Disorder, Narcotic Use, Back Pain, Back Injuries, Chronic Pain, Chronic Low-back Pain, Pain, Chronic, Pain;Back Low;Chronic, Pain, Back | CARBIDOPA, LEVODOPA, NAPROXEN | Its record names the disease | ClinicalTrials.gov | |
| NCT04895306 | Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial) | Phase 2 | 36 | Pain, Opioid Use, Androgen Deficiency, Back Pain | TESTOSTERONE CYPIONATE | Its record names the disease | ClinicalTrials.gov | |
| NCT02892591 | Cannabis Versus Oxycodone for Pain Relief | Phase 3 | 33 | Back Pain, Neck Pain | OXYCODONE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Prevention of Opioid Withdrawal vs Prevention of Physical Dependence: serious adverse events | 0 of 33 | 0 of 48 | 81 | NCT01549652 |
Source Trial comparisons
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0022861
GET https://conductscience.org/api/diseases/v1/EFO_0022861/drugs